Baudax Bio, Inc. Common Stock
BXRX
BXRX was delisted on the 15th of November, 2023.
31 hedge funds and large institutions have $5.58M invested in Baudax Bio, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 10 closing their positions.
2,024% more call options, than puts
Call options by funds: $361K | Put options by funds: $17K
75% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 4
0% more funds holding
Funds holding: 31 → 31 (0)
0% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 10
41% less capital invested
Capital invested by funds: $9.43M → $5.58M (-$3.85M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$336K |
| 2 |
State Street
Boston,
Massachusetts
|
+$266K |
| 3 |
Goldman Sachs
New York
|
+$141K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$116K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$44.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
-$294K |
| 2 |
BGIM
Brandywine Global Investment Management
Philadelphia,
Pennsylvania
|
-$282K |
| 3 |
Two Sigma Advisers
New York
|
-$239K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$151K |
| 5 |
Bank of New York Mellon
New York
|
-$131K |
BXRX Hedge Fund Activity: Q2 2021 in Review
31 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Baudax Bio, Inc. Common Stock (BXRX) for Q2 2021, worth a combined $5.58M — down 41% from $9.43M a quarter earlier.
Fund positioning in BXRX was balanced in Q2 2021: 10 funds opened new positions, 10 closed out, 7 added to existing stakes and 4 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $336K. The largest seller was Two Sigma Investments, exiting entirely with an estimated $294K sold.
- 31 institutional investors held Baudax Bio, Inc. Common Stock (BXRX) as of Q2 2021, unchanged from Q1 2021.
- Funds reported $5.58M of Baudax Bio, Inc. Common Stock stock for Q2 2021, down 41% quarter-over-quarter.
- 10 funds opened new Baudax Bio, Inc. Common Stock positions in Q2 2021 and 10 closed out, a net change of 0 holders.
- The largest Baudax Bio, Inc. Common Stock buyer in Q2 2021 was Morgan Stanley, an estimated $336K added.
- The largest Baudax Bio, Inc. Common Stock seller in Q2 2021 was Two Sigma Investments, an estimated $294K sold.
Based on aggregated 13F filings for Q2 2021.